Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination
Open accessPublished version of a preprint
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Abstract Dicer1 functions as a tumor suppressor in mouse models. In humans, somatic mutations are associated with many cancers in adults, and patients with DICER1 syndrome with DICER1 germline mutations are susceptible to childhood cancers. Dicer is phosphorylated by the ERK-MAP kinase pathway and because this pathway is activated in human cancers, we asked whether phosphorylated Dicer1 contributed to tumor development. In human endometrioid cancers, we discovered that phosphorylated DICER1 is significantly associated with invasive disease. To test a direct involvement of Dicer1 phosphorylation in tumor development, we studied mice with phosphomimetic alterations at the two conserved serines phosphorylated by ERK and discovered that a phosphomimetic Dicer1 drives tumor development and dissemination in two independent murine cancer models (KRas+/LA1 and p53+/−). Our findings demonstrate that phosphomimetic Dicer1 promotes tumor development and invasion. Significance: This work highlights the relevance of Dicer1 phosphorylation in mammalian tumor development and dissemination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a phosphomimetic mutation of DICER1, which is a core component of the RNA interference machinery mediating miRNA effects, precipitates aging and promotes tumor formation in mouse models.”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051 · cited 2×
“Toassess cancerphenotypes independently of developmental lethality displayed by the homozygousmutants, we used heterozygous Dicer mice in two distinct cancer models carrying KRas or p53 mutations (14, 15).”
BackgroundMethodDicer is essential for mouse development
Bernstein, E., Kim, S. Y., Carmell, M. A., Murchison, E. P., Alcorn, H., Li, M. Z., Mills, A. A., Elledge, S. J., Anderson, K. V., & Hannon, G. J. (2003) · Nature Genetics · doi:10.1038/ng1253 · Cited by 1,627
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 2×
“Toassess cancerphenotypes independently of developmental lethality displayed by the homozygousmutants, we used heterozygous Dicer mice in two distinct cancer models carrying KRas or p53 mutations (14, 15).”
BackgroundMethodDicer Is Required for Embryonic Angiogenesis during Mouse Development
Yang, W. J., Yang, D. D., Na, S., Sandusky, G. E., Zhang, Q., & Zhao, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413394200 · Cited by 541
DICER1: mutations, microRNAs and mechanisms
Foulkes, W. D., Priest, J. R., & Duchaine, T. F. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3802 · Cited by 539
Dicer1 functions as a haploinsufficient tumor suppressor
Kumar, M. S., Pester, R. E., Chen, C. Y., Lane, K., Chin, C., Lu, J., Kirsch, D. G., Golub, T. R., & Jacks, T. (2009) · Genes & Development · doi:10.1101/gad.1848209 · Cited by 442 · cited 2×
“Phosphomimetic Dicer1 cooperates with p53 heterozygosity in transformation TP53 loss is associatedwithDICER1mutations andan activated KRAS pathway inmany human tumors (4, 9, 18).”
BackgroundRakheja, D., Chen, K. S., Liu, Y., Shukla, A. A., Schmid, V., Chang, T.-C., Khokhar, S., Wickiser, J. E., Karandikar, N. J., Malter, J. S., et al. (2014) · Nature Communications · doi:10.1038/ncomms5802 · Cited by 236
Billingsley, C. C., Cohn, D. E., Mutch, D. G., Stephens, J. A., Suarez, A. A., & Goodfellow, P. J. (2015) · Cancer · doi:10.1002/cncr.29046 · Cited by 176
Self-citationPugh, T. J., Yu, W., Yang, J., Field, A. L., Ambrogio, L., Carter, S. L., Cibulskis, K., Giannikopoulos, P., Kiezun, A., Kim, J., et al. (2014) · Oncogene · doi:10.1038/onc.2014.150 · Cited by 175
Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo
Lambertz, I., Nittner, D., Mestdagh, P., Denecker, G., Vandesompele, J., Dyer, M. A., & Marine, J.-C. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.202 · Cited by 163 · cited 1×
“Lymphoma 0 5(5) Histiocytic sarcoma 0 6(6)”
Cited by
Meta-hallmarks of aging and cancer
López-Otín, C., Pietrocola, F., Roiz-Valle, D., Galluzzi, L., & Kroemer, G. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.001 · Cited by 529
Burger, K., Ketley, R. F., & Gullerová, M. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00061 · Cited by 64
“Recent studies have confirmed the importance of these carboxy-terminal phospho-residues for Dicer localization and function in phospho-mimetic Dicermouse models (Aryal et al., 2019).”
BackgroundKRAS Hijacks the miRNA Regulatory Pathway in Cancer
Bortoletto, A. S., & Parchem, R. J. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0296 · Cited by 33
Li, Y., Li, F., Pan, H., Huang, X., Yu, J. Z., Liu, X., Zhang, Q., Xiao, C., Zhang, H., & Zhang, L. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01643-y · Cited by 27
“The deregulation of phosphorylation is known to be involved in neoplastic disease [13, 14].”
BackgroundCardona, A. F., Chamorro, D. F., Ruíz-Patiño, A., Gómez, D. F., Muñoz, Á., Ardila, D. V., García-Robledo, J. E., Ordóñez‐Reyes, C., Sussmann, L., Mosquera, A., et al. (2023) · Neuro-Oncology Practice · doi:10.1093/nop/npad014 · Cited by 23
Metadata
- Authors
- Aryal, N. K., Pant, V., Wasylishen, A. R., Rimel, B. J., Baseler, L., El-Naggar, A. K., Mutch, D. G., Goodfellow, P. J., Arur, S., & Lozano, G.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Cedars-Sinai Medical Center (US)
- 5Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Washington University in St. Louis (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Corresponding author
- Arur, Swathi
- Lozano, Guillermina
- ORCID
- Venue
- Cancer Research
- Published
- 2019-05-15
- Volume
- 79
- Issue
- 10
- Pages
- 2662-2668
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC6522273
- OpenAlex
- W2924811454
- Cited by
- 17
- References
- 18
- Citations by year
- 2025: 4 · 2024: 2 · 2023: 5 · 2022: 4 · 2019: 2
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (CA82577, P50CA134254, P50CA16672)
- HHS | National Institutes of HealthHHS | National Institutes of Health (NIH) (GMR0198200)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- DICER1, phosphorylation, phosphomimetic mutations, ERK MAP kinase pathway, tumor progression, metastasis, tumor invasion, endometrioid carcinoma, KRAS, p53, tumor suppressor, DICER1 syndrome
- MeSH terms
- Animals, Disease Models, Animal, Mice, Inbred C57BL, Neoplasm Invasiveness, Neoplasms, Phosphorylation, Signal Transduction, Disease Progression, MAP Kinase Signaling System, Ribonuclease III, Mice, DEAD-box RNA Helicases, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination. https://app.cochat.ai/papers/10.1158/0008-5472.can-18-2460
- The paper
- Aryal, N. K., Pant, V., Wasylishen, A. R., Rimel, B. J., Baseler, L., El-Naggar, A. K., Mutch, D. G., Goodfellow, P. J., Arur, S., & Lozano, G. (2019). Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination. Cancer Research. https://doi.org/10.1158/0008-5472.can-18-2460
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.